ライフサイエンスコーパス: epoprostenol

1 he protocol; 4 patients transitioned back to epoprostenol.

2 better risk-benefit profile than intravenous epoprostenol.

3 sion has significantly improved with CCB and epoprostenol.

4 assessment of prognosis after treatment with epoprostenol.

5 Hemodynamics improved at 12 weeks with epoprostenol.

6 n 6 of 10 (60%) of those receiving long-term epoprostenol.

7 Over a period of 6-14 months, epoprostenol (10-28 ng/kg/min) therapy was associated wi

8 ry hypertension was treated with intravenous epoprostenol, 23 ng/kg/min, for a 4-month period, after

9 een introduced, and may have advantages over epoprostenol administration.

10 ed monotherapy with bosentan, sildenafil, or epoprostenol and combination therapy.

11 ges in pulmonary vascular resistance for the epoprostenol and control groups were -21 percent and +9

12 es in mean pulmonary-artery pressure for the epoprostenol and control groups were -8 percent and +3 p

13 es in mean pulmonary artery pressure for the epoprostenol and conventional therapy groups were -5.0 a

14 Twenty-one patients treated with epoprostenol and no patients receiving conventional ther

15 monary hypertension with chronic intravenous epoprostenol and now report the first patient with sever

16 ension; 14 underwent acute administration of epoprostenol, and no significant side effects were noted

17 Epoprostenol appears to have sustained efficacy in this

18 tension, although predictors of outcome with epoprostenol are not well characterized.

19 nary arterial hypertension were treated with epoprostenol at our institution.

20 ucted in systemic arteries with substance P, epoprostenol, atrial natriuretic peptide, and relaxin (c

21 Because of the inconsistent availability of epoprostenol before 1995, we defined a "recent medical e

22 s treprostinil at Week 12 versus intravenous epoprostenol before transition.

23 been studied: chronic intravenously infused epoprostenol, chronic subcutaneously infused treprostini

24 Therapeutic response to epoprostenol, defined by a reduction in the pulmonary va

25 Adverse events related to the epoprostenol delivery system included sepsis, cellulitis

26 The epoprostenol dose was increased monthly to the maximum t

27 Epoprostenol, epidural anesthesia and postoperative hemo

28 Epoprostenol, epidural anesthesia, and postoperative hem

29 long-term effects of continuous infusion of epoprostenol (epo) therapy on survival and pulmonary art

30 preservation, donor livers were infused with epoprostenol (ex situ, portal vein); recipients were giv

31 The long-term effects of epoprostenol exceeded the short-term pulmonary vasodilat

32 ponders with vasodilator testing and chronic epoprostenol for nonresponders.

33 ts of the continuous intravenous infusion of epoprostenol (formerly called prostacyclin) plus convent

34 Long-term use of epoprostenol further lowered PVR (-47% +/- 12% from base

35 he quality of life were improved only in the epoprostenol group (P < 0.01).

36 Four patients in the epoprostenol group and five in the conventional therapy

37 and Dyspnea-Fatigue Ratings improved in the epoprostenol group.

38 nd fewer new digital ulcers were seen in the epoprostenol group.

39 Intravenous epoprostenol has been demonstrated to decrease pulmonary

40 Recently, continuous intravenous infusion of epoprostenol has been demonstrated to improve symptomato

41 The long-term impact that epoprostenol has made on PPH remains to be defined.

42 Epoprostenol has markedly improved the treatment of pulm

43 Older patients treated with epoprostenol have significantly shorter survival, regard

44 nary-selective vasodilators, such as inhaled epoprostenol (iEPO) and nitric oxide (iNO), are essentia

45 Inhaled epoprostenol (iEPO) has been introduced worldwide as a c

46 are treated with CCB; they are treated with epoprostenol if they become nonresponders.

47 Intravenous epoprostenol improves long-term survival in PPH.

48 Our results indicate that treatment with epoprostenol improves survival in patients with Primary

49 last 10 years, starting with the approval of epoprostenol in 1998.

50 document the efficacy of inhaled aerosolized epoprostenol in a patient with portopulmonary hypertensi

51 ut period, all patients received intravenous epoprostenol in incrementally increasing doses; toleranc

52 pulmonary hemodynamic effects of intravenous epoprostenol in patients with moderate to severe pulmona

53 We now report the use of epoprostenol in the more specific instance of PPHTN.

54 manifest favorable hemodynamic responses to epoprostenol in the short term.

55 e no data examining the effects of long-term epoprostenol in this entity.

56 Chronic epoprostenol, in conjunction with a multidisciplinary, w

57 We conclude that epoprostenol infusion is effective in improving hemodyna

58 itric oxide as acute intraoperative therapy, epoprostenol infusion represents an additional therapeut

59 The pulmonary vascular response to epoprostenol infusion serves as a deciding factor for OL

60 ion were treated with continuous intravenous epoprostenol infusions.

61 The inhaled route of delivery of epoprostenol is potential alternative for the acute ther

62 lmonary hypertension, long-term therapy with epoprostenol lowers pulmonary vascular resistance beyond

63 monary vascular resistance when treated with epoprostenol (mean, 39+/-14 percent; P=0.002).

64 Exercise capacity improved with epoprostenol (median distance walked in 6 minutes, 316 m

65 was improved in the 41 patients treated with epoprostenol (median distance walked in six minutes, 362

66 Survival for all children treated with epoprostenol (n=35) at 1, 5, and 10 years was 94%, 81%,

67 ntan with or without concomitant intravenous epoprostenol or subcutaneous treprostinil therapy.

68 r riociguat), prostacyclin pathway agonists (epoprostenol or treprostinil), and endothelin pathway an

69 Epoprostenol plus conventional therapy or conventional t

70 esthetic sophistication, and availability of epoprostenol, PPHTN is no longer considered an absolute

71 rapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improv

72 matic patients, treatment with prostacyclin (epoprostenol) produced improvements in hemodynamics, qua

73 With current therapies such as epoprostenol, progression of disease is slowed, but not

74 e., for more than one year) with intravenous epoprostenol (prostacyclin) in patients with advanced pr

75 s "portopulmonary hypertension." Intravenous epoprostenol (prostacyclin) is a potent pulmonary and sy

76 during acute testing, continuous intravenous epoprostenol (prostacyclin, PGI2) improves haemodynamics

77 Ten patients received continuous epoprostenol (range, 8 days-30 months).

78 its delivery system, continuous intravenous epoprostenol remains the most efficacious treatment curr

79 Continuous intravenous administration of epoprostenol remains the treatment of choice in WHO func

80 e progression; i.e., death, transplantation, epoprostenol rescue, or >25% decrease in peak oxygen con

81 Acute infusion of epoprostenol resulted in a significant (p < 0.05) decrea

82 ere portopulmonary hypertension, intravenous epoprostenol resulted in a significant improvement (both

83 antithrombotic agents (macitentan, bosentan, epoprostenol, selexipag, sildenafil, tadalafil, and bera

84 The complexity of epoprostenol therapy (chronic indwelling catheters, reco

85 Observed survival with epoprostenol therapy at 1, 2, and 3 years was 87.8%, 76.

86 Chronic intravenous epoprostenol therapy has had a substantial impact on the

87 Continuous epoprostenol therapy improves exercise capacity and card

88 Side effects of epoprostenol therapy included jaw pain, nausea, and anor

89 Epoprostenol therapy was initiated and the rate of infus

90 ata suggest that transition from intravenous epoprostenol to intravenous treprostinil is safe and eff

91 n label study were switched from intravenous epoprostenol to intravenous treprostinil over 24 to 48 h

92 Hemodynamics improved at 12 weeks in the epoprostenol-treated patients.

93 We analyzed the effects of long-term epoprostenol treatment to determine features associated

94 Long-term epoprostenol was generally well tolerated and provides a

95 en from the total 77 patient cohort for whom epoprostenol was recommended but was unavailable.

96 Intravenous epoprostenol was the first Food and Drug Administration-

97 Effects of long-term infusion of epoprostenol were also evaluated.

98 patients diagnosed with PPH and treated with epoprostenol were followed for a mean of 36.3 months (me

99 = 27), all patients treated with intravenous epoprostenol were weaned off post-LT, and endothelin rec

100 onary hypertension successfully treated with epoprostenol who subsequently underwent successful liver

101 continues to do well, and at 3 months is off epoprostenol with near normal pulmonary artery pressures